Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rimexolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 10/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.61 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.61 |
| ▸ | AR | P10275 | 2/20 | 0.61 |
| ▸ | TNF | P01375 | 1/20 | 0.61 |
| ▸ | IL6 | P05231 | 1/20 | 0.61 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.61 |
| ▸ | GLUL | P15104 | 1/20 | 0.61 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.61 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimexolone SCHEMBL29030108 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL29030109 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL1651214 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL445300 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL13693339 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL19327140 | 0.94 | NR3C1 (0.88) | NR3C1PGRHIF1ALMNANR1I2 | |
| SCHEMBL9470879 | 0.92 | NR3C1 (0.86) | NR3C1PGRHIF1ALMNANR1I2 | |
| SCHEMBL9470890 | 0.92 | NR3C1 (0.86) | NR3C1PGRHIF1ALMNANR1I2 | |
| SCHEMBL9467046 | 0.91 | NR3C1 (0.84) | NR3C1PGRHIF1ALMNANR1I2 | |
| SCHEMBL9467031 | 0.91 | NR3C1 (0.84) | NR3C1PGRHIF1ALMNANR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2181704-B1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INT AG (CH) | 2015-05-06 | — | — | EP | claimed |
| EP-2181704-A2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG (CH) | 2010-05-05 | — | — | EP | claimed |
| EP-1594459-B1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INT AG (CH) | 2010-02-17 | — | — | EP | claimed |
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| EP-2181704-B1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INT AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| US-8481073-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-07-09 | — | — | US | disclosed |
| US-8460708-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-06-11 | — | — | US | disclosed |
| US-20120252905-A1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG | 2012-10-04 | — | — | US | disclosed |
| US-20100268288-A1 | ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2010-10-21 | — | — | US | disclosed |
| US-20050182463-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050169961-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-04 | — | — | US | disclosed |
| US-20050169960-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-04 | — | — | US | disclosed |
| US-20050158356-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-21 | — | — | US | disclosed |
| US-20050154374-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-14 | — | — | US | disclosed |
| US-20050152946-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-14 | — | — | US | disclosed |
| US-20050142162-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-30 | — | — | US | disclosed |
| US-20040260318-A1 | Anastomotic connector devices | ANGIOTECH INTERNATIONAL AG (CH) | 2004-12-23 | — | — | US | disclosed |
| US-20040225077-A1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG (CH) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050152946-A1 | Implantable sensors and implantable pumps and anti-scarring agents | MMP1, CDKN1A, MKI67 | NR3C1 528/4885PGR 758/4885HIF1A 272/4885 |
| US-20050169961-A1 | Implantable sensors and implantable pumps and anti-scarring agents | MMP1, CDKN1A, MKI67 | NR3C1 528/4885PGR 758/4885HIF1A 272/4885 |
| US-20050142162-A1 | Soft tissue implants and anti-scarring agents | MMP1, COL2A1, FN1 | NR3C1 822/4885PGR 175/4885HIF1A 259/4885 |
| US-20120252905-A1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | PGF, VCAM1, COL14A1 | NR3C1 3134/4885PGR 815/4885HIF1A 1434/4885 |
| US-20050154374-A1 | Implantable sensors and implantable pumps and anti-scarring agents | MMP1, CDKN1A, MKI67 | NR3C1 528/4885PGR 758/4885HIF1A 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.